Some epidemiological studies demonstrated that lung cancer susceptibility was not associated with NAT2 acetylator status.18,25,28,30,35 However, some investigators held the opinion that slow acetylator phenotype of NAT2 polymorphisms was associated with increased risk of lung cancer.20,24 In our meta-analysis, there was no significant association between slow acetylator phenotype of NAT2 polymorphisms and lung cancer risk. The gene discussed is NAT2; the disease is lung carcinoma.